Background: The objective of this study was to investigate the antitumor activity of selectively expanded γδ T cells in tumor-infiltrating lymphocytes (γδTILs) or tumor ascites lymphocytes (γδTALs) from patients with colorectal and ovarian epithelial carcinoma (OEC) in vitro and in vivo. Methods: γδTILs/TALs were expanded by the solid-phase antibody method; their cytolytic and proliferative activities in vitro were detected by the MTT method and 3H-TdR incorporation and their effect in vivo was evaluated by the nude mice model. Results: Expanded γδTILs from colorectal tumors demonstrated marked cytotoxicities to allogeneic human colon adenocarcinoma HR8348 and lymphoma Daudi cells, as well as xenogeneic murine thymoma EL-4 cell lines. Cytokines, including IL-2, IL-4, IL-12, IL-15, TNF-α and INF-γ, could promote the cytotoxicities of γδTILs to tumor cells, whereas IL-10, GM-CSF and TFG-β had no effect on such killing activities. Rested γδTILs could proliferate strongly in response to mitomycin C-treated Daudi and EL-4 tumor cells, but not to HR8348 tumor cells, suggesting that the latter might possess only cytotoxicity-related antigen recognized by γδTILs. Either αβTILs or γδTILs from patients with OEC displayed cytotoxicities to allogeneic or autologous OEC cell lines at a similar strength in vitro. Transferring γδTILs into Daudi cell-bearing BALB/c nude mice with an injection of IL-2 was able to maintain a high survival rate of the mice for 30 days, when compared with mice treated with αβTILs or without any treatment (p < 0.05). Without coinjection of IL-2, after 3 months of Daudi tumor inoculation, a high survival rate was observed in γδTIL-treated mice. Similarly, adoptive γδTALs from the ascites of patients with OEC transferred into nude mice displayed a stronger antitumor response to OEC SKOV3 cells than αβTALs in vivo. Tumor volumes in γδTAL-treated mice were smaller than in αβTAL-treated or non-TAL-treated mice within the period from day 23 to day 50 after tumor inoculation (p < 0.05). Fifty days after SKOV3 tumor inoculation, a decreasing trend of carcinogenic rate was observed in γδTAL-treated nude mice. Conclusion: Taken together, our results suggest that γδT cells could be a new candidate for adoptive immunotherapy in the future treatment of patients with cancer.

Keywords:
Tumor, Tumor-infiltrating lymphocytes, =γδ T cells, Cytotoxicity, Cytokine, Adoptive immunotherapy
1.
Haas W, Pereira P, Tonegawa S: Gamma/delta T cells. Annu Rev Immunol 1993;11:637–685.
2.
Raulet DH: The structure, function and molecular genetics of the gamma/delta T cell receptor. Annu Rev Immunol 1989;7:175–207.
3.
Zocchi MR, Ferrarini M, Rugarli C: Selective lysis of the autologous tumor by δTCS1+γδ+ tumor-infiltrating lymphocytes from human lung carcinomas. Eur J Immunol 1990;20:2685–2689.
4.
Nanno M, Seki H, Mathioudakis G, Suzuki R, Itoh K, Ioannides CG, Suzuki S, Chen PF, Platsoucas CD: γδ T cell antigen receptors expressed on tumor-infiltrating lymphocytes from patients with solid tumors. Eur J Immunol 1992;22:679–687.
5.
Yu S, He W, Chen J, Zhang F, Ba D: Expansion and immunological study of human tumor infiltrating gamma/delta lymphocytes in vitro. Int Arch Allergy Immunol 1999;119:31–37.
6.
Percy C, Van Holten V, Muir C (eds): International Classification of Diseases for Oncology, ed 2. Geneva, World Health Organization, 1990.
7.
Niu H, Zhang S, He W: Cytostasis of γδ T cell lines expanded from patients with ovarian epithelial carcinoma to tumor cell lines in vitro. Chin J Cancer Biother 2000;7:90–93.
8.
Kowalczyk D, Skorupski W, Kwias Z, Nowak J: Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br J Urol 1997;80:543–547.
9.
Watanabe N, Hizuta A, Tanaka N, Orita K: Localization of T cell receptor (TCR)-gamma delta + T cells into human colorectal cancer: Flow cytometric analysis of TCR-gamma delta expression in tumour-infiltrating lymphocytes. Clin Exp Immunol 1995;102:167–173.
10.
Liavaag PG, Johannessen AC, Nilsen R, Jonsson R: Analysis of T-cell receptor expressing lymphocytes infiltrating squamous cell carcinomas of the upper aerodigestive tract. Eur Arch Otorhinolaryngol 1994;251:452–456.
11.
Shimizu Y, Watanabe A, Whiteside TL: Memory T-lymphocytes are the main population of tumor-infiltrating lymphocytes obtained from human primary liver tumors. J Hepatol 1992;16:197–202.
12.
Takahashi I, Kiyono H: γδ T cells: Bodyguards and/or sleepers in the gut. Chem Immunol 1998;71:77–87.
13.
Choudhary A, Davodeau F, Moreau A, Peyrat MA, Bonneville M, Jotereau F: Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J Immunol 1995;154:3932–3940.
14.
Maeurer M, Zitvogel L, Elder E, Storkus WJ, Lotze MT: Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. Nat Immun 1995;14:188–197.
15.
Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96:6879–6884.
16.
Wesch D, Marx S, Kabelitz D: Comparative analysis of αβ and γδ T cell activation by Mycobacterium tuberculosis and isopentenyl pyrophosphate. Eur J Immunol 1997;27:952–956.
17.
Ferrarini M, Pupa SM, Zocchi MR, Rugarli C, Menard S: Distinct pattern of HSP72 and monomeric laminin receptor expression in human lung cancers infiltrated by gamma/delta T lymphocytes. Int J Cancer 1994;57:486–490.
18.
Rojas RE, Balaji KN, Subramanian A, Boom WH: Regulation of human CD4+ alphabeta T-cell-receptor-positive (TCR+) and gammadelta TCR+ T-cell responses to Mycobacterium tuberculosis by interleukin-10 and transforming growth factor beta. Infect Immun 1999;67:6461–6472.
19.
Boullier S, Poquet Y, Debord T, Fournie JJ, Gougeon ML: Regulation by cytokines (IL-12, IL-15, IL-4 and IL-10) of the Vgamma9Vdelta2 T cell response to mycobacterial phosphoantigens in responder and anergic HIV-infected persons. Eur J Immunol 1999;29:90–99.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.